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Once again in 2015, the ADA and the EASD have
opportunely pointed the need of a patient-centered
approach for the management of hyperglycemia in indi-
viduals with type 2 diabetes (T2DM) [1]. A HbA1c cut off
\7 % has been suggested with more or less stringent tar-
gets to be individually pursued according to patient/disease
features (PDFs), including: (a) risks associated with
hypoglycemia; (b) disease duration; (c) life expectancy;
(d) comorbidities; (e) vascular complications; and (f) pa-
tient’s attitude. Since the ADA/EASD made clear that scale
for such approach ‘‘is not designed to be applied rigidly but
to be used as a broad construct to guide clinical decision
making,’’ many clinicians will appreciate to be told how to
measure the above-mentioned PDFs. We addressed this
issue by firstly proposing a way to score individual PDFs
and then investigating the distribution of such scores in a
real-life clinical set.
Data from 400 consecutive out-patients with T2DM
attending two research-based hospitals in Central-Southern
Italy, ‘‘Casa Sollievo della Sofferenza,’’ Scientific Institute
in San Giovanni Rotondo (SGR, n = 200) and ‘‘Sapienza’’
University Policlinico Umberto I Hospital in Rome (Rome,
n = 200) were collected.
Each of the six ADA/EASD suggested PDF was scored
equal to 0 (good), 1 (intermediate) or 2 (poor). Scoring
criteria (Table 1) were pre-specified in a collaborative
fashion by all authors and then used independently by four
authors who are experienced diabetologists (i.e., taking
care of[20 patients/week since 10–35 years; AP, SDC in
SGR; MF, SM in Rome). Within each hospital, concor-
dance between scores attributed to each single PDF in each
patient was observed in more than 95 % cases. In the
absence of agreement, the final score was attributed upon
confrontation between the two examiners. Mean values
attributed to each single PDF were summed to obtain the
total individual PDFs score.
Patients’ clinical features are summarized in Table 2.
Median value of individual PDFs score was 6, with only
one patient scoring 0 and no patients scoring 11 or 12.
Patients were then grouped according to score 0–2,
(n = 41, 10.2 %), 3–4 (n = 85, 21.2 %), 5–6 (n = 136,
34.0 %), 7–8 (n = 111, 27.8 %) and 9–10 (n = 27,
6.8 %), arbitrarily defined as ‘‘very good,’’ ‘‘good,’’ ‘‘in-
termediate,’’ ‘‘poor’’ and ‘‘very poor,’’ respectively.
According to ADA/EASD patient-centered approach,
which patients should be targeted to an intensive anti-dia-
betes therapy (HbA1c\ 7 %)? Probably, only those with
‘‘very good’’ or ‘‘good’’ PDFs scores? If so, more than two-
thirds of our patients should be targeted to more relaxed
attempts (HbA1c\ 7.5 % or more). In fact, the majority of
study patients had a score ranging from ‘‘intermediate’’ to
‘‘very poor,’’ while only 31.4 % show a ‘‘very good’’ or
‘‘good’’ score. A similar conclusion could have been drawn
according to a totally independent ADA suggestion,
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specifically devoted to elderly people ([65 years). In this
subgroup, the ADA recommends a level of HbA1c\ 7.5 %
rather than 7 % if patients are otherwise healthy with intact
cognitive and functional status, more relaxed targets are
indicated for elderly with comorbidities (HbA1c\ 8.0 %
or even\8.5 %) [2]. Of note, 255 (63.7 %) of our study
patients were in fact C65 years old, a finding which is
similar to that reported in larger epidemiological surveys,
and thus candidates, by the only virtue of age, to a relaxed
HbA1c target (\7.5 % or more). Such a proportion is
similar to that obtained by using the PDFs score (68.6 % of
our patients scored as ‘‘intermediate,’’ ‘‘poor’’ or ‘‘very
poor’’ score), thus somehow validating the results obtained
by PDFs score and reinforcing the idea that, in our clinical
set, intensive anti-diabetes therapy is suggestible for a
minority of patients.
Are our findings interpretable in the context of meta-
analyses of trials addressing the impact of intensive glu-
cose lowering therapy on all-cause mortality which
showed, quite unexpectedly, no benefit at all? Probably
yes; in fact, among possible explanations of such coun-
terintuitive negative result is certainly—on one side—the
deleterious role of severe hypoglycemia [3, 4], which is
ineludibly associated with intensive anti-diabetes therapy,
but—on the other side—also the possibility that intensive
treatment should be limited to younger patients, with short
disease duration and lack of major chronic complications
and comorbidities, all patients whose PDFs score would
conceivably be defined as ‘‘very good’’ or ‘‘good’’ by our
scoring method.
Although we recognize that our scoring method does not
derive from objective standardized measurements (espe-
cially the one referring to patient’s attitude, which is only
based on personal judgment of experienced diabetologists),
it is of note that more than 95 % agreement was observed
between the two examiners within the each hospital, thus
internally validating it.
Table 1 Scoring criteria of the
six patient/disease features,
ranging from 0 (good) to 1
(intermediate) or 2 (poor)
Score 0 1 2
Duration of diabetes (years) \5 5–10 [10
Age (years) \45 45–65 [65
or
Life expectancy (years)a [10 5–10 \5
Comorbidities Absent Mildb Severec
Cardiovascular disease
or
Advanced microangiopathy
Absent Present without clinical events Present with clinical eventsd
Hypoglycemic episodes Never Moderate Severee
Patient’s attitudef Good Intermediate Poor
a According to the risk defined by our previously published risk engine for predicting all-cause mortality in
patients with type 2 diabetes (De Cosmo et al. Diabetes Care 2013; 36:2830–2835. doi: 10.2337/dc12-1906;
also available as a free web-based calculator at http://www.operapadrepio.it/rcalc/rcalc.php): high risk was
given a score equal to 2, intermediate risk equal to 1 and low risk equal to 0
b Hearing impairment, arthritis, chronic obstructive bronchitis, depression, gastrointestinal and muscu-
loskeletal diseases, obesity
c Congestive heart failure, hip fracture, tumors, memory or cognitive impairment, vision reduction
d Myocardial infarction, heart failure, pulmonary edema, stroke, diabetic foot, amputation, blindness,
retinal detachment, nephrosis, acute renal failure, end stage renal disease
e Requiring assistance of another person to actively administer carbohydrate, glucagon, or other resusci-
tative actions
f Based on the personal judgment of experienced physicians
Table 2 Clinical features of the 400 study patients with type 2
diabetes
Sex (M/F) 249/151
Age (years) 66.8 ± 10.3
Body mass index (kg/m2) 29.0 ± 5.3
Smokers [n (%)] 58 (14.5)
Duration of diabetes (years) 12.8 ± 9.5
Glycated hemoglobin (%) 7.6 ± 1.7
Anti-hyperglycemic therapy
Diet alone [n (%)] 44 (11.0)
Oral antidiabetes drugs [n (%)] 198 (49.5)
Insulin ± oral antidiabetes drugs [n (%)] 88 (39.5)
Anti-hypertensive treatment [n (%)] 314 (78.5)
Anti-dyslipidemic treatment [n (%)] 252 (63.0)
Data are number (n) and percentage (%) or mean ± SD
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A further limitation of our scoring method, which is
based on the arbitrary assumption of an equivalent role
played by each PDF, is that the contribution of each feature
is not ‘‘weighted’’ according to its own importance in
determining the level of treatment intensiveness. This
might end up to different individual HbA1c targeting. For
example, it is conceivable, and probably agreeable, that
individuals with previous major cardiovascular events,
even in the absence of other counter-indications (thus
scoring only 2), should be preferentially targeted to a
relaxed glycemic control. It is worth noting that, under this
scenario (or similar ones), our scoring method, if any,
underestimates the proportion of patients targetable to
more relaxed HbA1c levels. In all, though some suggestions
from experienced people have been recently offered [5],
specifically designed prospective studies aimed at objec-
tively addressing the individual weight to be attributable to
each PDF are definitively needed.
In conclusion, despite the above-mentioned limitations,
we believe our present report has the merit of proposing a
method for measuring ADA/EASD suggested PDFs to
eventually be used for pursuing a patient-centered glucose
lowering treatment. According to the proposed method, in
the real-life clinical set of Central-Southern Italy, the
majority of patient attending diabetes clinics from
research-based hospitals seems not to be eligible to inten-
sive anti-diabetes treatments. Additional attempts are nee-
ded to address the generalizability of our finding and to
better shape the specific weight of each single PDF in
determining the degree of intensiveness of anti-diabetes
treatments.
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